Understanding and targeting resistance mechanisms in NSCLC
J Rotow, TG Bivona - Nature Reviews Cancer, 2017 - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
Precision medicine in non-small cell lung cancer: Current applications and future directions
Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
[HTML][HTML] Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
Background Rearranged during transfection (RET) gene fusions are a validated target in
non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and …
non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and …
Mechanisms of receptor tyrosine kinase activation in cancer
Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
A whole-genome reference panel of 14,393 individuals for East Asian populations accelerates discovery of rare functional variants
Underrepresentation of non-European (EUR) populations hinders growth of global precision
medicine. Resources such as imputation reference panels that match the study population …
medicine. Resources such as imputation reference panels that match the study population …
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
A Drilon, N Rekhtman, M Arcila, L Wang, A Ni… - The Lancet …, 2016 - thelancet.com
Background RET rearrangements are found in 1–2% of non-small-cell lung cancers.
Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall …
Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall …
TRKing down an old oncogene in a new era of targeted therapy
A Vaishnavi, AT Le, RC Doebele - Cancer discovery, 2015 - AACR
The use of high-throughput next-generation sequencing techniques in multiple tumor types
during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding …
during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding …
[HTML][HTML] Comprehensive genomic characterization of squamous cell lung cancers
Cancer Genome Atlas Research Network - Nature, 2012 - ncbi.nlm.nih.gov
Lung squamous cell carcinoma (lung SqCC) is a common type of lung cancer, causing
approximately 400,000 deaths per year worldwide. Genomic alterations in lung SqCC have …
approximately 400,000 deaths per year worldwide. Genomic alterations in lung SqCC have …